Last reviewed · How we verify
cortexolone 17α-propionate
At a glance
| Generic name | cortexolone 17α-propionate |
|---|---|
| Also known as | CB-03-01, clascoterone (USAN, INN) |
| Sponsor | Cassiopea SpA |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (PHASE3)
- 1% Clascoterone Cream for the Treatment Acne Vulgaris (PHASE3)
- Topical Anti-Androgens in Pilonidal Sinus Disease (PHASE2)
- A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients (PHASE4)
- A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne (PHASE4)
- A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2) (PHASE3)
- A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne (PHASE4)
- A Study Assessing the Efficacy and Safety of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cortexolone 17α-propionate CI brief — competitive landscape report
- cortexolone 17α-propionate updates RSS · CI watch RSS
- Cassiopea SpA portfolio CI